

# Michael A Barras Bpharm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1487633/publications.pdf>

Version: 2024-02-01

77  
papers

1,405  
citations

430442

18  
h-index

395343

33  
g-index

79  
all docs

79  
docs citations

79  
times ranked

2167  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Pharmacists reducing medication risk in medical outpatient clinics: a retrospective study of 18 clinics. <i>Internal Medicine Journal</i> , 2023, 53, 95-103.  | 0.5 | 8         |
| 2  | Platelet Function Assays for the Diagnosis of Aspirin Resistance. <i>Platelets</i> , 2022, 33, 329-338.  | 1.1 | 9         |
| 3  | Evaluation of two European risk models for predicting medication harm in an Australian patient cohort. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 679.   | 0.8 | 0         |
| 4  | Exploring factors of uneven use of telehealth among outpatient pharmacy clinics during COVID-19: A multi-method study. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3602-3611.                        | 1.5 | 10        |
| 5  | Benefits, challenges and contributors to the introduction of new hospital-based outpatient clinic pharmacist positions. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100119.                     | 0.6 | 3         |
| 6  | Toward a Learning Health Care System: A Systematic Review and Evidence-Based Conceptual Framework for Implementation of Clinical Analytics in a Digital Hospital. <i>Applied Clinical Informatics</i> , 2022, 13, 339-354. | 0.8 | 10        |
| 7  | Treatment strategies for clozapine-induced hypotension: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210929.  | 1.2 | 6         |
| 8  | Scoping Review of Studies Evaluating Frailty and Its Association with Medication Harm. <i>Drugs and Aging</i> , 2022, 39, 333-353.   | 1.3 | 7         |
| 9  | A randomised trial of pharmacist-led discharge prescribing in an Australian geriatric evaluation and management service. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 847-857.                            | 1.0 | 3         |
| 10 | Development and validation of the Adverse Inpatient Medication Event model (AIME). <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1512-1524.  | 1.1 | 12        |
| 11 | Patient harm from cardiovascular medications. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110274.  | 1.0 | 5         |
| 12 | Systematic review of machine learning models for personalised dosing of heparin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4124-4139.  | 1.1 | 10        |
| 13 | An evaluation of pharmacist activity in hospital outpatient clinics. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 328-332.   | 0.5 | 5         |
| 14 | Conversion of other opioids to methadone: a retrospective comparison of two methods. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, 201-204.  | 0.8 | 1         |
| 15 | ROS directly activates transforming growth factor $\hat{1}^2$ type 1 receptor signalling in human vascular smooth muscle cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129463.              | 1.1 | 18        |
| 16 | Interventions designed to improve the safety and quality of therapeutic anticoagulation in an inpatient electronic medical record. <i>International Journal of Medical Informatics</i> , 2020, 135, 104066.                | 1.6 | 13        |
| 17 | A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery. <i>Drugs</i> , 2020, 80, 1889-1899.   | 4.9 | 9         |
| 18 | Transit Care Hub pharmacist: improving patient flow within the hospital. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1319-1325.  | 1.0 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Identifying medication harm in hospitalised patients: a bimodal, targeted approach. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862097551.  | 1.0 | 1         |
| 20 | Assessing Communication Behaviours of Hospital Pharmacists: How Well Do the Perspectives of Pharmacists, Patients, and an Independent Observer Align?. <i>Journal of Language and Social Psychology</i> , 2020, 39, 626-652. | 1.2 | 1         |
| 21 | Unfractionated heparin dosing in obese patients. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 462-473.  | 1.0 | 6         |
| 22 | Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study". <i>Clinical Drug Investigation</i> , 2020, 40, 287-288.   | 1.1 | 1         |
| 23 | Economic benefits of pharmacy technicians practicing at advanced scope: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1344-1353.  | 1.5 | 15        |
| 24 | Integrating a pharmacist into the perioperative setting. <i>Australian Health Review</i> , 2020, 44, 563-568.  | 0.5 | 4         |
| 25 | Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?. <i>Clinical Pharmacokinetics</i> , 2019, 58, 389-399.  | 1.6 | 20        |
| 26 | Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1645-1657.   | 0.8 | 6         |
| 27 | Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 387-393.  | 1.0 | 9         |
| 28 | Developing Preliminary Steps in a Pharmacist Communication " Patient Outcome Pathway. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 72, .   | 0.1 | 2         |
| 29 | How hospital pharmacists prioritise patients at high-risk for medication harm. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1266-1273.  | 1.5 | 16        |
| 30 | Defining and classifying terminology for medication harm: a call for consensus. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 137-145.  | 0.8 | 35        |
| 31 | Developing Preliminary Steps in a Pharmacist Communication - Patient Outcome Pathway. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 72, 271-281.  | 0.1 | 0         |
| 32 | Systematic review of predictive risk models for adverse drug events in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 846-864.   | 1.1 | 52        |
| 33 | Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .   | 1.4 | 3         |
| 34 | Hospital pharmacists' and patients' views about what constitutes effective communication between pharmacists and patients. <i>International Journal of Pharmacy Practice</i> , 2018, 26, 450-457.                            | 0.3 | 13        |
| 35 | Therapeutic drug monitoring: using Bayesian methods to evaluate hospital practice. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 522-529.   | 0.5 | 6         |
| 36 | Reply to Iuga and Genaidy "Comment on Falconer et al.". (2018) "the need for specific adverse drug reaction outcomes". <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1857-1857.                                | 1.1 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Using Discursis to enhance the qualitative analysis of hospital pharmacist-patient interactions. PLoS ONE, 2018, 13, e0197288.   | 1.1 | 5         |
| 38 | Endothelial function and dysfunction: Impact of metformin. , 2018, 192, 150-162.   |     | 82        |
| 39 | Using EMR-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review. Therapeutic Advances in Drug Safety, 2018, 9, 559-573.   | 1.0 | 71        |
| 40 | Individualised medicine: why we need Bayesian dosing. Internal Medicine Journal, 2017, 47, 593-600.  | 0.5 | 40        |
| 41 | Investigating strategies used by hospital pharmacists to effectively communicate with patients during medication counselling. Health Expectations, 2017, 20, 1121-1132.  | 1.1 | 22        |
| 42 | The type and incidence of adverse drug events in ageing medical inpatients and their effect on length of hospital stay. Journal of Pharmacy Practice and Research, 2017, 47, 347-354.  | 0.5 | 8         |
| 43 | A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer, 2017, 25, 607-613. | 1.0 | 19        |
| 44 | Drug dosing in obese adults. Australian Prescriber, 2017, 40, 189-193.   | 0.5 | 72        |
| 45 | Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay. Therapeutic Drug Monitoring, 2016, 38, 59-63.  | 1.0 | 3         |
| 46 | New oral anticoagulants: appropriateness of prescribing in real-world setting. Internal Medicine Journal, 2016, 46, 812-818.   | 0.5 | 51        |
| 47 | Examining hospital pharmacists' goals for medication counseling within the communication accommodation theoretical framework. Research in Social and Administrative Pharmacy, 2016, 12, 747-755.   | 1.5 | 4         |
| 48 | Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6698-6702.   | 1.4 | 33        |
| 49 | Inpatient smoking cessation "turn to your clinical pharmacist. Australian and New Zealand Journal of Public Health, 2016, 40, 498.   | 0.8 | 2         |
| 50 | Direct oral anticoagulants: New drugs with practical problems. How can nurses help prevent patient harm?. Australian Journal of Cancer Nursing, 2016, 18, 408-411.   | 0.8 | 4         |
| 51 | Hospital pharmacists' perceptions of medication counseling: A focus group study. Research in Social and Administrative Pharmacy, 2016, 12, 756-771.  | 1.5 | 16        |
| 52 | Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. Australian Health Review, 2016, 40, 86.  | 0.5 | 26        |
| 53 | Comparison of 2 Weight-Based Heparin Dosing Nomograms in Neurology and Vascular Surgical Patients. Therapeutic Drug Monitoring, 2015, 37, 33-39.   | 1.0 | 1         |
| 54 | Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy. Journal of Oncology Pharmacy Practice, 2015, 21, 293-295.  | 0.5 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | The development and evaluation of an oncological palliative care deprescribing guideline: the "OncPal deprescribing guideline"™. <i>Supportive Care in Cancer</i> , 2015, 23, 71-78.  | 1.0 | 112       |
| 56 | A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1910-1910.                                       | 0.6 | 1         |
| 57 | Reducing the risk of harm from intravenous potassium: A multi-factorial approach in the haematology setting. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 323-331.  | 0.5 | 6         |
| 58 | Improving Care Transitions in Individuals Frequently Admitted to the Hospital. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1994-1996.   | 1.3 | 6         |
| 59 | Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. <i>Supportive Care in Cancer</i> , 2014, 22, 1113-1119.   | 1.0 | 64        |
| 60 | Reporting a Population Pharmacokineticâ€“Pharmacodynamic Study: A Journalâ€™s Perspective. <i>Clinical Pharmacokinetics</i> , 2014, 53, 111-122.  | 1.6 | 30        |
| 61 | Abnormal laboratory results: Anti-Xa assays. <i>Australian Prescriber</i> , 2013, 36, 98-101.   | 0.5 | 9         |
| 62 | Medicinal mishap: Dabigatran â€“ a new safe drug to replace an old poison?. <i>Australian Prescriber</i> , 2012, 35, 64-65.   | 0.5 | 1         |
| 63 | Bayesian Optimisation of Tobramycin Dosing in Paediatric Patients with Cystic Fibrosis. <i>Journal of Pharmacy Practice and Research</i> , 2011, 41, 183-187.   | 0.5 | 6         |
| 64 | Recurrent readmissions in medical patients: A prospective study. <i>Journal of Hospital Medicine</i> , 2011, 6, 61-67.  | 0.7 | 128       |
| 65 | Individualized Dosing of Enoxaparin for Subjects With Renal Impairment Is Superior to Conventional Dosing at Achieving Therapeutic Concentrations. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 482-488.  | 1.0 | 14        |
| 66 | Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 615-623.   | 1.0 | 35        |
| 67 | Current dosing of lowâ€“molecularâ€“weight heparins does not reflect licensed product labels: an international survey. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 520-528.   | 1.1 | 17        |
| 68 | Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins. <i>Clinical Pharmacokinetics</i> , 2010, 49, 567-571.  | 1.6 | 10        |
| 69 | Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , 2010, 31, 21-4. | 3.3 | 98        |
| 70 | Modelling the occurrence and severity of enoxaparinâ€“induced bleeding and bruising events. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 700-711.  | 1.1 | 19        |
| 71 | Myalgia in Patients on Highâ€“Dose and Lowâ€“toâ€“Moderate Dose Statin Therapy. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 202-206.   | 0.5 | 1         |
| 72 | Individualized Compared With Conventional Dosing of Enoxaparin. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 882-888.  | 2.3 | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Pharmacists Investigating Adverse Penicillin Responsesâ€”Pilot Study. Journal of Pharmacy Practice and Research, 2007, 37, 200-203.                               | 0.5 | 0         |
| 74 | Are Patients on Longâ€”Term Corticosteroids Receiving Bone Loss Therapy?. Journal of Pharmacy Practice and Research, 2006, 36, 29-31.                             | 0.5 | 0         |
| 75 | Patients' Understanding of Drug Allergy and Documentationâ€”Is There a Link?. Journal of Pharmacy Practice and Research, 2005, 35, 276-278.                       | 0.5 | 3         |
| 76 | Teaching people with Parkinsonâ€”s disease about their medication. Nursing Older People, 2005, 17, 14-20.   | 0.1 | 21        |
| 77 | Infusion reaction incidence after switching all patients to an infliximab biosimilar in an Australian hospital. Journal of Pharmacy Practice and Research, 0, , . | 0.5 | 0         |